Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort.

At 24 months, while associations in the total RA group did not reach statistical significance, they were significant for non-LDA in patients with seronegative RA when measured using SDAI (OR (95% CI): 21.5 (2.83 to 462.4), p=0.002 for the univariable analysis and 29.9 (2.5 to 109.2), p=0.01 for the multivariable analysis) and CDAI (OR (95% CI): 8.5 (1.51 to 70.2), p=0.015 for the univariable analysis) ( table 5 ).

also in 111,027 other papers

1 In the total RA population, the largest differences in baseline antibody positivity between non-remission and remission patients, and correspondingly the highest OR, were observed at 9 months, with the non-remission SDAI therapy response approaching significance (22.7% non-rem vs 9.3% rem; OR (95% CI): 2.86 (0.97 to 10.5), p=0.057 for multivariable analysis) ( table 6 ).

also in 2,640 other papers

Similarly, in patients with seronegative status, baseline antibody reactivity showed a trend at 9 months toward association with SDAI non-remission (OR (95% CI): 4.44 (0.84 to 34.95), p=0.081 for multivariable analysis) ( table 7 ).

also in 53,322 other papers